Department of Epidemiology, Maastricht University, Maastricht, the Netherlands.
Department of Radiology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.
Br J Cancer. 2024 May;130(9):1561-1570. doi: 10.1038/s41416-024-02633-7. Epub 2024 Mar 11.
No studies are available in which changes over time in characteristics and prognosis of patients with interval breast cancers (ICs) and screen-detected breast cancers (SDCs) have been compared. The aim was to study these trends between 1995 and 2018.
All women with invasive SDCs (N = 4290) and ICs (N = 1352), diagnosed in a southern mammography screening region in the Netherlands, were included and followed until date of death or 31 December 2022.
The 5-year overall survival rate of women with SDCs increased from 91.4% for those diagnosed in 1995-1999 to 95.0% for those diagnosed in 2013-2018 (P < 0.001), and from 74.8 to 91.6% (P < 0.001) in the same periods for those with ICs. A similar trend was observed for the 10-year survival rates. After adjustment for changes in tumour characteristics, the hazard ratio (HR) for overall survival was 0.47 (95% confidence interval (CI): 0.38-0.59) for women with SDCs diagnosed in the period 2013-2018, compared to the women diagnosed in the period 1995-1999. For the women with ICs this HR was 0.27 (95% CI: 0.19-0.40).
The prognosis of women with ICs has improved rapidly since 1995 and is now almost similar to that of women with SDCs.
目前尚无研究比较随时间推移,间隔期乳腺癌(IC)和筛查期乳腺癌(SDC)患者特征和预后的变化。本研究旨在比较 1995 年至 2018 年期间的这些变化趋势。
所有在荷兰南部一个乳腺筛查区域诊断为浸润性 SDC(N=4290)和 IC(N=1352)的女性患者均纳入本研究,并随访至死亡或 2022 年 12 月 31 日。
SDC 患者的 5 年总生存率从 1995-1999 年诊断患者的 91.4%提高到 2013-2018 年诊断患者的 95.0%(P<0.001),IC 患者的生存率从 74.8%提高到 91.6%(P<0.001)。在同一时期,10 年生存率也呈现出类似的趋势。经肿瘤特征变化调整后,与 1995-1999 年诊断的患者相比,2013-2018 年诊断的 SDC 患者的总生存风险比(HR)为 0.47(95%可信区间(CI):0.38-0.59)。IC 患者的 HR 为 0.27(95% CI:0.19-0.40)。
自 1995 年以来,IC 患者的预后迅速改善,目前与 SDC 患者的预后几乎相似。